[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"complex-abdominal-aortic-aneurysms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:complex-abdominal-aortic-aneurysms":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100638810","patient-reported-quality-of-life-after-open-surgery-for-complex-abdominal-aortic-aneurysms-a-prospective-study-100638810",false,"NCT07580443","Patient-Reported Quality of Life After Open Surgery for Complex Abdominal Aortic Aneurysms: A Prospective Study","Inclusion Criteria:\n\n* Patients over 18 years old\n* Patients undergoing open surgical repair for complex abdominal aortic aneurysms (AAAs), including juxtarenal, pararenal and suprarenal\u002Fparavisceral aneurysms\n* Patients treated for asymptomatic or symptomatic non ruptured aneurysms\n* Patients who are able and willing to provide informed, complete, and accurate responses to the SF-36 questionnaire\n\nExclusion Criteria:\n\n* Patients under 18 years old\n* Patients treated for ruptured abdominal aortic aneurysms\n* Patients with incomplete data, or who denied consent\n* Patients with cognitive impairment or other conditions that prevent them from reliably completing the SF-36 questionnaires.","ALL","18 Years",{"count":18,"type":19},125,"ESTIMATED","OBSERVATIONAL","STUDY DURATION: January 2026 - December 2027 Each participant will be followed for 12 months postoperatively.\n\nBACKGROUND AND RATIONALE: Complex abdominal aortic aneurysms (cAAAs)-including juxtarenal, pararenal, and suprarenal aneurysms-can be treated via open surgical repair (OSR) or complex endovascular techniques (f\u002FbEVAR). While OSR may offer better long-term durability, especially in fit patients, there is currently a lack of data on patient-reported quality of life (QoL) outcomes following OSR for cAAAs. This study aims to fill this gap and support shared decision-making in vascular surgery.\n\nOBJECTIVES:\n\n* Primary Objective: To assess changes in health-related quality of life (HRQoL) using the Short Form-36 (SF-36) questionnaire at five predefined time points (baseline, discharge, 1 month, 6 months, and 12 months post-surgery).\n* Secondary Objectives: To analyze QoL differences by patient subgroups (e.g., age, comorbidities, aneurysm type), to assess correlations with clinical outcomes (e.g., complications, hospital stay), and to evaluate the impact of postoperative complications on QoL.\n\nSTUDY POPULATION:\n\n* Inclusion criteria: Adults (≥18 years) undergoing OSR for non-ruptured complex AAAs (juxtarenal, pararenal, suprarenal).\n* Exclusion criteria: Patients under 18, those with ruptured AAAs, cognitive impairment, or those unable to complete the SF-36 questionnaire.\n\nPARTICIPATING CENTERS:\n\n* Ospedale Regionale di Lugano (EOC), Switzerland\n* Luzerner Kantonsspital, Switzerland\n* Centre Hospitalier Universitaire de Montpellier, France\n\nSTUDY PROCEDURES:\n\n* Administration of the SF-36 questionnaire at five time points: preoperative, at discharge (within 7 days), and at 1, 6, and 12 months postoperatively.\n* Data collection includes demographic information, aneurysm characteristics, in-hospital and follow-up outcomes, and questionnaire responses.",[23],"Complex Abdominal Aortic Aneurysms",[25,26,27,28],"Complex abdominal aortic aneurysms","SF-36","Quality of Life","Open surgical repair","RECRUITING","2026-05-13",{"date":32,"type":33},"2026-05-15","ACTUAL",{"date":35,"type":33},"2026-03-18",{"date":37,"type":19},"2027-12-31",{"name":39,"class":40},"Prouse Giorgio","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100633637","clinical-performance-and-safety-assessment-of-the-use-of-icover-balloon-expandable-covered-stent-ivascular-implanted-as-bridging-stent-in-fevar-fenestrated-endovascular-aortic-repair-for-the-treatment-of-complex-abdominal-aortic-aneurysms-100633637","NCT07529275","Clinical Performance and Safety Assessment of the Use of iCover Balloon Expandable Covered Stent (iVascular) Implanted as Bridging Stent in FEVAR (Fenestrated Endovascular Aortic Repair) for the Treatment of Complex Abdominal Aortic Aneurysms","fenCo","Inclusion Criteria:\n\n1. Patient suitable for treatment of a juxta, para-renal, suprarenal or thoracoabdominal aneurysm with a fenestrated endoprosthesis in accordance with current indications and guidelines for the management of abdominal aortic aneurysms (aneurysm \\> 5 centimetres for women and \\> 5.5 centimetres for men and\u002For growth \\> 5 mm in 6 months or 1 centimetre in 1 year).\n2. The fenestrated endograft must be designed in a way that positions the fenestrations directly in front of the orifice of the target vessel, ensuring that the distance between the fenestration and the orifice of the target vessel does not exceed 5 mm.\n3. Anatomy and patient strictly in accordance with the Instructions For Use (IFU) of the fenestrated endograft chosen to be implanted:\n\n   1. Cook Medical: Zenith Fenestrated AAA Endovascular Graft\n   2. Terumo Aortic: TREO and Anaconda Fenestrated Stent Grafts\n   3. JOTEC (part of Artivion): E-xtra design engineering.\n4. Additional iCover stent, if necessary, could be placed in the same target artery (2 iCovers stents max as bridging stent for each fenestration).\n5. Landing zone in the target vessel of at least 10 mm.\n6. Target arteries (renal arteries, superior mesenteric artery, celiac trunk) with a diameter between 5 and 10 mm.\n7. Angulation of the aorta at the level of the target vessels \\\u003C 45 degrees.\n8. No early significant branching from the target vessel with a potential risk of coverage and subsequent significant risk of target organ infarctions.\n9. Age \\> 55 years.\n10. Patient having notified his consent to this study and willing to comply with specified follow-up evaluations at the specified times.\n11. Patient affiliated to or benefiting from a social security system.\n12. Patient with life expectancy \\> 12 months.\n\nExclusion Criteria:\n\n1. Patients contraindicated for anti-platelet therapy.\n2. Patients with uncontrolled haematological disorders or heparin-induced thrombocytopenia.\n3. Chronic or acute aortic dissection.\n4. Patients refusing treatment.\n5. Patients who are pregnant or wish to become pregnant.\n6. Patients scheduled for major or life-saving surgery within 30 days of the fenestrated stent procedure.\n7. Patients considered hemodynamically unstable or requiring emergency treatment.\n8. Patients with severe arteriopathy leading to adverse outflow, which may impair bridging stent patency on the targeted artery.\n9. Thrombus in the aortic sealing zone and target arteries with thickness \\> to 3 mm.\n10. Stenosis (\\>50%) or occlusion of target arteries or distal disease resulting in poor iCover stent outflow.\n11. Patients allergic to stent materials (L605) and\u002For PTFE.\n12. Patients requiring a hybrid aortic technique with branches, semibranches or chimneys.\n13. Patient who has been implanted with any stent type or brand other than iCover as a bridging stent in any target artery.\n14. Patients with infectious\u002Fmycotic aneurysms.\n15. Angulation between renal artery and aortic wall \\\u003C 30 degrees.\n16. Patients with complex iliac accesses out the IFUs of the fenestrated endograft chosen to be implanted (COOK Medical \u002F Terumo Aortic\u002FJotec-Artivion) with the iCover Bridging stent.\n17. Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period that may interfere with the results of this study.\n18. Myocardial infarction or stroke within 3 months prior to the procedure.\n19. Patients with an unstable angina pectoris or heart insufficiency NYHA 3 or 4.\n20. Patients with ASA classification 5 or higher.\n21. Patients with physician modified endografts or in situ laser FEVAR.","55 Years",{"count":50,"type":19},165,"INTERVENTIONAL",[53],"NA","fenCo is a European multicentre, prospective study to evaluate the use of the iCover covered stents as bridging stents for reno-visceral target vessel during fEVAR for the treatment of complex abdominal aortic aneurysms.",[23],[57,58,59],"FEVAR","bridging stent","complex abdominal aortic aneurysms","2026-04-13",{"date":62,"type":33},"2026-04-14",{"date":64,"type":33},"2026-02-16",{"date":66,"type":19},"2028-09-30",{"name":68,"class":69},"iVascular S.L.U.","INDUSTRY",24]